OTC:
$LUDG

Latest PR

SPARKS, NV / ACCESSWIRE / September 22, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the Company has filed a patent on proprietary technology, the “Ludwig mRNA Inflammatory Index™.” The patent covers the application of messenger ribonucleic acid (mRNA) in diagnosing, managing, and evaluating inflammatory disease patient treatment response in heart disease, diabetes, autoimmune disease, preeclampsia, and bladder, colon, and breast cancer.

SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the Company has started discussions with Emerson Urology Associates, Concord, MA regarding initiation of a clinical study to evaluate the response of bladder cancer patients to BCG immunotherapy. A confidentiality agreement has been signed with Dr. John Libertino, MD, Director of Emerson Urology Associates.

SPARKS, NV / ACCESSWIRE / August 18, 2022 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a provider of innovative medical technologies, announced today another significant milestone in the company’s recently announced new business model. The company has also engaged a public accounting firm as its independent auditor while retaining the services of Newlan Law Firm, PLLC, an experienced Flower Mound, Texas, securities firm, to assist the company in achieving its future IPO aspirations. The company remains committed to increasing operational transparency and to becoming an SEC-reporting company in the near term.

Invest in a
Stock

– Invest in a company that is dedicated to helping you and your family

– Potentially life-saving technology

– Research has already yielded promising results

– A sound investment for the future

– Get in on the ground floor of a company with massive potential for growth

– Invest in breakthrough healthcare technologies

– Benefit from strong leadership and experienced management

– Grow your portfolio as the company grows and succeeds

Ludwig Announces Engagement of
Marvin S. Hausman MD
as Chief Science Consultant

The potential for growth at Ludwig Enterprises is great because they have hired Dr. Hausman for their scientific advisory board. Dr. Hausman is an experienced Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience. He has held various positions with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx. With this level of experience and expertise, Dr. Hausman will be a valuable asset to Ludwig Enterprises as they continue to develop new and innovative products.

19

July 2022

Dr. Marvin S. Hausman MD,
Chairman of Ludwig's Scientific Advisory Board (SAB) has appointed
Dr. Kyle H. Ambert, PhD to its SAB

Facebook Twitter Google-plus

Ludwig Enterprises has made an excellent decision by hiring Dr. Ambert for their scientific advisory board. With his extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics, Dr. Ambert will be able to help Ludwig Enterprises grow by using these technologies to improve their business processes. He has already shown his ability to make a difference at Nike, Inc., and we have no doubt that he will do the same for Ludwig Enterprises.

His prior employment history includes positions at Intel Corp. and the National Library of Medicine. Dr. Ambert graduated from Oregon Health & Science University with a PhD in Biomedical Informatics.

21

July 2022

About Ludwig Enterprises

Ludwig is an innovative technology and health-related company that uses inflammatory genetic markers to diagnose disease, diagnose, and assess pre- and post-treatment responses. Advancements in medical technology have awarded us with cutting-edge genetic tools, unheard-of even a generation ago. These genetic tools have the potential to not only detect diseases early but also to customise treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genetic methodology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, preeclampsia, and cancer.

This early detection may allow doctors to take steps to diagnose and manage disease before it progresses and causes serious health problems. Ludwig’s innovative testing approach is not only practical but also has the potential to save the healthcare industry billions of dollars in costs.

With a virtually untapped market and a billion-dollar healthcare industry, Ludwig is poised to significantly impact how we think about disease and live longer, healthier lives.

Who they are?

Ludwig Enterprises, Inc. has been an innovative technology and health related company. Ludwig is endeavoring to return to and expand healthy living and other health technology products.

Ludwig mRNA Inflammatory index™️

- The Ludwig mRNA Inflammatory index™ can discover hidden gene patterns related to inflammatory causation of specific diseases, establish diagnoses, and show response to treatment.  - The artificial intelligence division with bioinformatics and deep machine learning experts will help the company search, classify, and mine different available biological databases.  - Shares of the company are available for purchase.

Ms. Anne Blackstone named CEO and Sole Director

Anne Blackstone, CRNA, has a strong background in medicine working in many prestigious posts managing healthcare. That led her to managing special projects in health technology which later, introduced her to mRNAforLife where she took over the CEO position with your strong leadership skills and deep knowledge of the importance of the company's products in healthcare.

Dr. Kyle H. Ambert, PhD appointed to LUDWIG’s Scientific Advisory Board

Dr. Ambert is currently Director of Data Science at Nike, Inc., and has extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics. His previous experience includes postings with the National Library of Medicine and Intel Corp. Dr. Ambert holds a PhD in Biomedical Informatics from Oregon Health & Science University.

AI is the future

The company announced it had established an Artificial Intelligence division to mine biological databases for valuable patient information. Ludwig is utilizing these databases to research and investigate the causes and effects of inflammation within our bodies.

"Ludwig acquired valuable proprietary research data from a significant genetics firm"
Proprietary Research
“Dr. Marvin S. Hausman, MD, a 40-year noted clinician, research scientist, and inventor, has accepted the company's Chief Science Consultant position”
Company's Chief Science Consultant
“Ludwig also acquired an mRNA patient genetic database; "Grace Health" cheek samples from breast, bladder, and colon cancer patients have been collected. The company will use these m-RNA inflammatory genetic markers to assist in disease diagnosis, monitoring, and assessment of pre and post-treatment responses. Objective: Establish a unique "Ludwig mRNA Inflammatory Index™.”
Objective: Establish a unique "Ludwig mRNA Inflammatory Index™
Ludwig formed an artificial intelligence division with bioinformatics and deep machine learning experts. The focus is to search, classify, and mine different available biological databases. The proprietary Ludwig mRNA Inflammatory index™ has the potential to discover hidden gene patterns related to inflammatory causation of specific diseases, establish diagnoses, and show response to treatment.
AI Division Formed

Ludwig Enterprises, Inc. has been an innovative technology and health related company. Ludwig is endeavoring to return to and expand healthy living and other health technology products. The Board of Directors believes this course change returning to our core focus to be in the best interest of Ludwig shareholders.

Buy Equity in Ludwig Enterprises

Shares of the company offer a unique opportunity in the market for investors.

mRNA Patient Genetic Database

The mRNA patient genetic database offers great potential for disease diagnosis, monitoring, and assessment of pre and post-treatment responses.

Breakthrough Technology

The Ludwig mRNA Inflammatory Index™ will set a new standard in the industry.

Research Leader

Ludwig Enterprises's mRNA research has already yielded promising results.

Massive Potential

Ludwig Enterprises is committed to helping people overcome their illnesses, and shareholders can feel confident in the company's future.

“The cutting-edge technology described in this patent has the potential to help people live a healthier and longer life,” stated Marvin S. Hausman, MD, Chairman of the Ludwig Scientific Advisory Board (SAB). “The patent covers the company’s proprietary testing methods that can measure genetic inflammatory biomarkers for diseases like heart disease, preeclampsia, or cancer. These diseases are often silent and asymptomatic before raising their ‘ugly head.’ The Ludwig technology has the potential to predict disease development and allow doctors to monitor a patient’s response and modify treatment steps as needed.”

The molecule mRNA carries genetic information needed to produce proteins by cells. Because the data in DNA cannot be decoded directly into proteins, it is first transcribed or copied into mRNA. Each molecule of mRNA encodes the information for one protein. The mRNA molecules are transported through a cell’s outer envelope into the cytoplasm, where they are translated by the rRNA of ribosomes, cellular structures which perform biological protein synthesis. Specific amounts of amino acids in a protein and their sequence determine the protein’s unique properties; for example, muscle protein and hair protein contain the same 20 amino acids, but the sequences of these amino acids in the two proteins are quite different. Segments of mRNA are like a written message, and these “words” are translated into specific amino acids that make up protein. An example is mRNA vaccines that teach our cells how to make a protein that will trigger an immune response inside our bodies. Like all vaccines, mRNA vaccines benefit people who get vaccinated by protecting against diseases like COVID-19 without risking the potentially severe consequences of getting sick.

The Ludwig mRNA Inflammatory Index™ will be used in the recent announcement: “Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study.

Clinically, high-risk non-muscle-invasive bladder cancer (NMIBC) is treated with adjuvant intravesical instillations of Bacillus Calmette-Guérin (BCG) after surgery to eradicate residual disease and hence reduce the frequency of recurrence and progression (Babjuk, 2017; Lindskrog, 2021).

The Ludwig proprietary “Index” has the potential to create a genetic signature in patients with bladder cancer. This genetic signature provides a potential framework in bladder cancer clinical trials to optimize early diagnosis and clinical management with anticancer therapy.

 

The market for this advanced early detection system is also virtually untapped, with little competition in the billion-dollar healthcare industry. Ludwig can use these cutting-edge technologies to help people live longer, healthier lives by providing sensitive testing methods that have the potential to detect genetic markers of inflammation in diseases, such as heart disease or cancer, before there are obvious symptoms. Doctors can potentially monitor and modify a patient’s positive or negative response in the treatment process – potentially saving billions in chronic disease healthcare costs.

Invest in
One of the Leading Research Firm ​

The Board of Directors believes that returning to our core focus on health technology and healthy living will be in the best interest of Ludwig shareholders. The U.S. healthcare IT market is valued at $96,930.26 Million in 2020, and is projected to reach $344,074.09 Million by 2030, registering a CAGR of 13.4% from 2021 to 2030.

This provides a strong foundation for Ludwig’s future growth and profitability. Additionally, Ludwig has a strong track record of innovation and success in the healthcare technology market, which we believe will give us a competitive edge in this growing sector. For these reasons, the Board of Directors believes that Ludwig is a good investment for shareholders.

Before patents and major announcements affect the stock.

It is wise to buy a stock at its lowest.*

Get in on the ground floor of a quickly growing company. Buy Shares in $LUDG*

If your brokerage firm does not list $LUDG, go for E*TRADE, Scotto Trade or Schwab.

*Investment advice should only be taken at its face value, all investors are advised to conduct their own research with due diligence to make wise decisions.

Privacy Policy

Legal Dislaimer

© PubCo Insight, 2022
Facebook-f Twitter Youtube Linkedin